Demographic and Clinical Characteristics of Patients with Sustained and Switching Treatments Using Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs: A Multicenter, Observational Cross-Sectional Study for Rheumatoid Arthritis-Reference-Cited by-同舟云学术

Demographic and Clinical Characteristics of Patients with Sustained and Switching Treatments Using Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs: A Multicenter, Observational Cross-Sectional Study for Rheumatoid Arthritis

Published:2021-12-01 Issue:1 Volume:9 Page:223-241
ISSN:2198-6576
Container-title:Rheumatology and Therapy
language:en
Short-container-title:Rheumatol Ther

Author:

Ataman Sebnem,Sunar Ismihan^ORCID,Bodur Hatice,Melikoglu Meltem Alkan,Cay Hasan Fatih,Capkin Erhan,Akgul Ozgur,Cevik Remzi,Gogus Feride,Kamanli Ayhan,Yurdakul Fatma Gul,Gurer Gulcan,Yagci Ilker,Rezvani Aylin,Duruoz Mehmet Tuncay

Publisher

Springer Science and Business Media LLC

Subject

Immunology and Allergy,Rheumatology

Link

https://link.springer.com/content/pdf/10.1007/s40744-021-00403-y.pdf

Reference37 articles.

1. Zhao J, Zhou W, Wu Y, Ji P, Yan X, Yang L, et al. FRI0143 The efficacy and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse of rheumatoid arthritis. Ann Rheum Dis. 2020;79(Suppl 1):655.

2. Vodencarevic A, Tascilar K, Hartmann F, Reiser M, Hueber AJ, Haschka J, et al. Advanced machine learning for predicting individual risk of flares in rheumatoid arthritis patients tapering biologic drugs. Arthritis Res Ther. 2021;23(1):67.

3. Murray K, Turk M, Alammari Y, Young F, Gallagher P, Saber T, et al. Long-term remission and biologic persistence rates: 12-year real-world data. Arthritis Res Ther. 2021;23(1):25.

4. Kameda H, Hirata A, Katagiri T, Takakura Y, Inoue Y, Takenaka S, et al. Prediction of disease flare by biomarkers after discontinuing biologics in patients with rheumatoid arthritis achieving stringent remission. Sci Rep. 2021;11(1):6865.

5. Nekvindová L, Vencovský J, Pavelka K, Horák P, Křístková Z, Závada J. Switching first-line targeted therapy after not reaching low disease activity within 6 months is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry. Arthritis Res Therapy [Internet]. 2021; 23(1):[11]. Available from: http://europepmc.org/abstract/MED/33407803. Doi: https://doi.org/10.1186/s13075-020-02393-8. https://europepmc.org/articles/PMC7789592. https://europepmc.org/articles/PMC7789592?pdf=render

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence of cardiovascular diseases and traditional cardiovascular risk factors in patients with rheumatoid arthritis: a real-life evidence from BioSTAR nationwide registry;Rheumatology International;2023-12-29

2. Interleukin-6 Suppression by Different TNF Inhibitors in Rheumatoid Arthritis Patients During Maintenance Therapy;Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 );2023-09-04

3. Assessing the construct validity of musculoskeletal ultrasound and the rheumatoid arthritis foot disease activity index (RADAI-F5) for managing rheumatoid foot disease;Rheumatology Advances in Practice;2023-01-01